Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PrecisionPhage is a Finnish biotechnology company specializing in the development and application of bacteriophage-based solutions to combat antimicrobial resistance (AMR). The company utilizes a proprietary platform for the rapid identification, characterization, and high-titer production of therapeutic phages tailored to specific bacterial pathogens. Their service-oriented model, often described as Phage-as-a-Service, provides researchers and clinicians with customized phage cocktails and diagnostic tools for personalized medicine. By integrating genomic analysis with phage-host interaction data, PrecisionPhage aims to provide a scalable alternative to traditional antibiotics for multi-drug resistant infections.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PrecisionPhage.